Medscape
The US Food and Drug Administration (FDA) has approved a novel formulation combining rizatriptan and the nonsteroidal anti-inflammatory drug meloxicam (Symbravo, Axome Therapeutics) for the acute treatment of migraine with or without aura in adults. “Symbravo incorporates Axsome’s rapid absorption technology and mechanisms that target multiple migraine attack pathways,” the company explained in a news …
Read More
FDA Clears NSAID/Triptan Combo for Migraine in Adults
Raleigh Schroeder
21:22
The US Food and Drug Administration (FDA) has approved a novel formulation combining rizatriptan and the nonsteroidal anti-inflammatory drug meloxicam (Symbravo, Axome Therapeutics) for the acute treatment of migraine with or without aura in adults. “Symbravo incorporates Axsome’s rapid absorption technology and mechanisms that target multiple migraine attack pathways,” the company explained in a news
